Gilead Announces Harvoni Results from Phase 2 and Phase 3 Studies
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with limited or no treatment options, including patients with decompensated cirrhosis, patients with HCV recurrence following a liver transplant and patients who failed previous treatment with other direct acting antivirals.
Hepatitis C Patients May Live Longer With Treatment
For patients with chronic hepatitis C, liver problems can sometimes shorten their lives. But a new study found that successful treatment might ease some life expectancy concerns for these patients.
FDA Approves Combo Treatment for Hepatitis C
The US Food and Drug Administration (FDA) approved a new combination treatment for hepatitis C infection Wednesday.
Hepatitis C Rx Gets Additional Approval as Combo Treatment with Sofosbuvir
Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved OLYSIO® (simeprevir), a hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen.
FDA Approves New Combo Rx for Hepatitis C
US regulators have approved a new pill to treat hepatitis C. That pill, which is a combination of two medications, could simplify treatment for patients.
FDA Approves First Combination Pill to Treat Hepatitis C
The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
Researchers Find Possible Link Between Tobacco and Oral HPV
Smoking has been tied to health issues of all types. Now, smokers might have another reason to kick the habit — oral human papillomavirus (HPV).
FDA Approves New Rx for Combination with Other HIV Medications
On September 24, 2014, FDA approved Vitekta (elvitegravir) 85 mg and 150 mg tablets.
FDA Approves New Rx for Combination with HIV Medications
On September 24, 2014, FDA approved Tybost (cobicistat) 150 mg tablets. Tybost is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection.
Recommendations to Reduce STDs Focus on Teens, At-Risk Adults
Sexually transmitted diseases (STDs) continue to be a major health concern. New recommendations call for more measures to address this problem.